早孕期子痫前期筛查与预测
子痫前期是孕产妇和围产儿死亡的重要原因,孕16周前开始低剂量阿司匹林可显著降低早产型子痫前期发生率。ACOG与NICE基于母体危险因素的筛查方法检出率欠佳,而FMF三联试验(母体因素联合平均动脉压、子宫动脉搏动指数及血清胎盘生长因子)对早发型和早产型子痫前期检出率分别达90%和75%(假阳性率10%),联合低剂量阿司匹林可降低早产型子痫前期发生率62%。
要点
- 孕16周前开始低剂量阿司匹林可显著降低早产型子痫前期发生率。
- NICE推荐基于危险因素的筛查对早产型和足月型子痫前期检出率分别为41%和34%(假阳性率10%)。
- FMF三联试验对早发型和早产型子痫前期检出率分别为90%和75%(假阳性率10%),优于母体危险因素筛查。
核心结论
- 基于母体危险因素的NICE和ACOG筛查方法性能欠佳,FMF三联试验筛查性能优于传统方法,联合低剂量阿司匹林可降低早产型子痫前期发生率62%。
研究设计与样本
- 综述,总结现有文献中早孕期子痫前期筛查的不同方法、专业组织推荐、风险评估各部件的质量评估及临床实施。
主要发现
- NICE推荐筛查对早产型和足月型子痫前期检出率分别为41%和34%,假阳性率10%。
- 2013年ACOG推荐筛查对早产型和足月型子痫前期检出率分别为5%和2%,假阳性率0.2%。
- FMF三联试验对早发型和早产型子痫前期检出率分别为90%和75%,假阳性率10%。
- 使用FMF预测模型后给予低剂量阿司匹林可使早产型子痫前期发生率降低62%。
- FMF三联试验预防1例早产型子痫前期需筛查250人。
关键数值与推荐
- ACOG和NICE推荐基于母体危险因素筛查子痫前期,将每个危险因素视为独立筛查试验,检出率和筛查阳性率相加。
- 多数早孕期预测模型未进行或未通过外部验证,FMF三联试验已通过成功内部和外部验证。
临床怎么用
- 采用FMF三联试验进行早孕期子痫前期筛查,随后给予低剂量阿司匹林。
- 维持最佳筛查性能的关键是建立生物标志物测量的标准化方案并定期进行质量评估。
- 常用质量控制工具包括累积和(cumulative sum)与目标图(target plot),累积和可敏感检测随时间的小偏移并易识别偏移点,目标图易解读和可视化但对小偏差不敏感。
局限性
- 多数早孕期预测模型未进行或未通过外部验证。
- 目标图对检测小偏差不敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preeclampsia is a major cause of maternal and perinatal morbidity and mortality. Early-onset disease requiring preterm delivery is associated with a higher risk of complications in both mothers and babies. Evidence suggests that the administration of low-dose aspirin initiated before 16 weeks' gestation significantly reduces the rate of preterm preeclampsia. Therefore, it is important to identify pregnant women at risk of developing preeclampsia during the first trimester of pregnancy, thus allowing timely therapeutic intervention. Several professional organizations such as the American College of Obstetricians and Gynecologists (ACOG) and National Institute for Health and Care Excellence (NICE) have proposed screening for preeclampsia based on maternal risk factors. The approach recommended by ACOG and NICE essentially treats each risk factor as a separate screening test with additive detection rate and screen-positive rate. Evidence has shown that preeclampsia screening based on the NICE and ACOG approach has suboptimal performance, as the NICE recommendation only achieves detection rates of 41% and 34%, with a 10% false-positive rate, for preterm and term preeclampsia, respectively. Screening based on the 2013 ACOG recommendation can only achieve detection rates of 5% and 2% for preterm and term preeclampsia, respectively, with a 0.2% false-positive rate. Various first trimester prediction models have been developed. Most of them have not undergone or failed external validation. However, it is worthy of note that the Fetal Medicine Foundation (FMF) first trimester prediction model (namely the triple test), which consists of a combination of maternal factors and measurements of mean arterial pressure, uterine artery pulsatility index, and serum placental growth factor, has undergone successful internal and external validation. The FMF triple test has detection rates of 90% and 75% for the prediction of early and preterm preeclampsia, respectively, with a 10% false-positive rate. Such performance of screening is superior to that of the traditional method by maternal risk factors alone. The use of the FMF prediction model, followed by the administration of low-dose aspirin, has been shown to reduce the rate of preterm preeclampsia by 62%. The number needed to screen to prevent 1 case of preterm preeclampsia by the FMF triple test is 250. The key to maintaining optimal screening performance is to establish standardized protocols for biomarker measurements and regular biomarker quality assessment, as inaccurate measurement can affect screening performance. Tools frequently used to assess quality control include the cumulative sum and target plot. Cumulative sum is a sensitive method to detect small shifts over time, and point of shift can be easily identified. Target plot is a tool to evaluate deviation from the expected multiple of median and the expected median of standard deviation. Target plot is easy to interpret and visualize. However, it is insensitive to detecting small deviations. Adherence to well-defined protocols for the measurements of mean arterial pressure, uterine artery pulsatility index, and placental growth factor is required. This article summarizes the existing literature on the different methods, recommendations by professional organizations, quality assessment of different components of risk assessment, and clinical implementation of the first trimester screening for preeclampsia.
引用
- Chaemsaithong P, Sahota DS, Poon LC, et al. First trimester preeclampsia screening and prediction. Am J Obstet Gynecol. 2020. PMID: 32682859. doi:10.1016/j.ajog.2020.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。